Peter Keller

Over the last decade as a biotech entrepreneur, Peter Keller has helped to steer companies such as Aelin Therapeutics, Divide & Conquer, Disarm Therapeutics (acquired by Eli Lilly and Company), Selecta Biosciences (Nasdaq: SELB), and Inventiva (Nasdaq: IVA) through various stages of corporate development, ranging from business planning, defining and executing R&D strategy, to securing private and public funding. Before his years in the startup arena, Peter was a Vice President at Abbott Laboratories and Solvay Pharmaceuticals, where he was involved in Abbott’s $6.2 billion acquisition of Solvay and led the subsequent integration of the two companies. Before that, he was Associate Principal at McKinsey & Co, and Senior Consultant at Simon-Kucher & Partners.

Peter has a Master of Science degree from the Karlsruhe Institute of Technology (KIT) in Karlsruhe, Germany, in both Industrial Engineering and Business Administration.